{"analyses":[{"ciLowerLimit":"0.296","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.528","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.395","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.59","upperLimit":"7.33","value":"6.70"},{"groupId":"OG001","lowerLimit":"9.79","upperLimit":"13.70","value":"11.37"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) in the absence of progression, whichever came first. Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment. Pharmacodynamic: Sum of diameters increased by greater than or equal to (\\>=)20 percent (%) and \\>=5 millimeter (mm) from nadir (including baseline if it was smallest sum).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received chemotherapy with pemetrexed 500 milligrams per meter square (mg/m\\^2) Intraveous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin area under the concentration-time curve of 5 (AUC 5) IV infusion administered on Day 1 for up to 4 cycles, and then as maintenance monotherapy until disease progression. Following the primary analysis, the study was transitioned to an open-label extension (OLE) phase, and participants either continued to receive the chemotherapy or crossover to amivantamab in the OLE phase.","id":"OG000","title":"Arm B: Chemotherapy Alone"},{"description":"Participants received amivantamab 1400 milligrams (mg) (1750 mg if body weight is greater than or equal to (\\>=) 80 kilograms \\[kg\\]) by IV infusion once weekly starting from Cycle 1 Day 1 up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \\>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 up to Cycle 5 Day 1. Participants received chemotherapy with pemetrexed 500 mg/m\\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin area under the concentration-time curve of 5 milligrams per milliliter (mg/mL) per minute (AUC 5) was administered as an IV infusion on Day 1, for up to 4 cycles, and then as maintenance monotherapy until disease progression. Following the primary analysis, the study was transitioned to an OLE phase, and participants continued to receive amivantamab plus chemotherapy in the OLE phase.","id":"OG001","title":"Arm A: Amivantamab + Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all randomized participants, classified according to their assigned treatment arm regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"From randomization to either disease progression or death whichever occurs first (up to 29 months)","title":"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)","type":"PRIMARY","unitOfMeasure":"Months"}